Advisory Board

Dr. Nirmal K. GangulyChairman JIPMER &

Ex. Director General, ICMR

Dr. Barry BloomProfessor and past Dean

Harvard School of Public Health

D.S. BrarChairman

GVK Biosciences

Dr. William ChinExecutive Dean of Research

Harvard Medical School

Dr. Victor DzauChancellor of Health Affairs

Duke University

Dr. Ansbert GadickeFounder & Managing Partner

MPM Capital

Dr. Martin MackayPresident Global R&D

AstraZeneca

Dr. Ivan GergelExecutive Vice President R&D

Endo Pharmaceuticals

Dr. David LaceySr. Vice President &

Head of Research, Amgen

Dr. John LeonardSenior Vice PresidentPharma R&D, Abbott

Joel MarcusChairman & CEO

Alexandria

Helmut M. Schühsler, PhDManaging Partner

TVM Capital

Kiran Mazumdar-ShawChairman

Biocon

Peter Mueller, PhD

Vertex PharmaceuticalsExecutive Vice President R&D

Dr. Michael RosenblattExecutive Vice President and CMO

Merck & Co.

Panel Discussions Covering

• Drug Discovery and Collaborative Research• R&D Models: Lessons Learned for BioPharma• Industry-Academic Partnerships• Clinical Research – Opportunities and Challenges• Best Practices for Making Alliances Work

• Restructuring R&D to Maximize Productivity & Innovation• Diabetes- Science, Research Trends and Investor Perspective• Funding innovation, Cross Border Investments and M&A trends in the BioPharma & Healthcare• Presentation of Position Paper by Boston Consulting Group

Pre Summit Strategy sessions (by invitation only): External Research Strategies Clinical Research/Industry-Academic Partnerships

Networking Tea Breaks, Hosted Lunch, Cocktails & High Power Networking Reception

Register online at www.usaindiachamber.org Limited seats. No walk-ins or at the door registration

*Program Subject to Change

USA-India Chamber of Commercepresents its annual

US-India BioPharma & Healthcare SummitThursday, June 23, 2011: 10-00 AM to 7-30 PM

President's Ballroom, Hyatt Cambridge, Massachusetts, USA

www.usaindiachamber.org

USA-India Chamber of CommerceA c c e l e r a t i n g U S A - I n d i a T r a d e & I n v e s t m e n t s

The innovation-driven ecosystem fostered by the USA-India Chamber of Commerce has led to meaningful research and technology partnerships between global and Indian companies. I have been involved with this platform for the last few years and it is a great feeling to see it evolve as the Summit of Choice for global research and technology leaders and investors.

K.V. SubramaniamPresident & CEO, Reliance Life Sciences and Advisory Board Member of the US-India BioPharma & Healthcare Summit

Dr. Mikael DolstenPresident, Worldwide R&D, Pfizer and Advisory Board Member of the US-India BioPharma & Healthcare Summit

Biopharma and biotech companies have a strong interest in the continued growth of India's innovative drug research industry – to improve public health in India and the world. Pfizer has a global network of academic alliances and strategic partnerships, including collaborations with several Indian Biopharma companies and CROs, to accelerate our delivery of differentiated medicines. This summit, organized by the USA-India Chamber of Commerce, by connecting companies with high quality drug designers and developers in India, is valuable to the industry and to patients.

Biotechnology has emerged as an important area of research and enterprise in India. The Government of India has been very supportive of this sector and has encouraged innovation and entrepreneurship through novel and innovative schemes, both for the public and private sector. The USA-India Chamber of Commerce has been playing an active role in the development of business ties between India and the US. I am sure the Summit will result in developing stronger ties between US and India in the field of Biotechnology.

Shri Pawan Kumar BansalMinister of Parliamentary Affairs, Science & Technology and Earth Sciences

Major global pharma companies are looking at India seriously with a huge market potential. I hope the leadership of these companies will also look at India as a strategic partner for their global drug discovery and development initiatives. We have seen the USAIC's annual Summit making immense contributions by bringing the key global BioPharma industry and Indian stakeholders together. I look forward to receiving recommendations deliberated at the annual Summit.

Shri Srikant Kumar JenaMinister of State Ministry of Chemicals & Fertilizers

Hon'ble Prime Minister of India has declared this as a decade of innovation. Global partnerships particularly with leadership countries such as United States are a key component of establishing global best practices. We fully recognize that an educated and effective human resource, physical infrastructure, sustained intellectual property policy and practice, science based and efficient regulation, hassle free business and trade practices are absolutely essential to fulfill the national vision of a quality innovation system.

Dr. M.K. BhanSecretary to the Government of India, Department of Biotechnology and Advisory Board Member of the US-India BioPharma & Healthcare Summit

For the last five years, I have observed the annual US-India BioPharma & Healthcare Summit play a significant role in forging partnerships between the global BioPharma and Indian companies. USAIC has been able to involve and engage Global BioPharma R&D leaders and key stakeholders to foster innovation. These interactions have led to innovative business ideas, new partnerships and business.

Hari S BhartiaCo - Chairman & MD, Jubilant Life Sciences and Advisory Board Member of the US-India BioPharma & Healthcare Summit

Dr. Naresh TrehanChairman Medanta - The Medicity and Advisory Board Member of the US-India BioPharma & Healthcare Summit

Global partnerships are vital for the future of medicine. India can be a key partner in safe and rapid development of therapies targeted at significant health problems. These partnerships can produce research that will enable development of drugs and devices to improve health around the world.

Dr. Allen SpiegelDean, Albert EinsteinCollege of Medicine

Dr. Paul StoffelsWorldwide Chairman

Pharmaceuticals Group Johnson & Johnson

Mervyn Turner, PhD Chief Strategy Officer

Merck & Co

Raju Kucherlapati, PhD Department of GeneticsHarvard Medical School

Dr. Inder Verma Irwin & Joan Jacobs Chair in

Exemplary Life ScienceThe Salk Institute

Karun RishiPresident, USA-India Chamber of Commerce

USA-India Chamber of Commerce has created a vibrant purpose driven innovation ecosystem bringing together all stakeholders: healthcare and life sciences executives, investors, academia and policy makers. Our annual Summit has become THE BioPharma event in the world to learn, share, deliberate, network and benefit for senior executives focused on Drug Discovery & Development, Licensing, Clinical Research, Healthcare, Innovation, M&A, Deal Flow and Emerging Markets. I encourage the active participation of all stakeholders who share our purpose of working together for an innovation driven healthier world.

Knowledge Partner

THE BOSTON CONSULTING GROUP